Progression of axial spondyloarthritis
Современная ревматология, 2021 The spectrum of bone lesions in axial spondyloarthritis is of great interest. With inflammation and mechanical influence concurrence in the background, both tissue gain and tissue loss in a particular bone area can occur simultaneously.
Sh. F. Erdes, T. V. Korotaeva
doaj +1 more source
Work Disability in Axial Spondyloarthritis [PDF]
Current Rheumatology Reports, 2020 AbstractPurpose of ReviewAxial spondyloarthritis (axSpA) is a chronic inflammatory disease that typically affects people of working age. Work-related outcomes are therefore important to study, both from an individual but also a societal perspective. Through this review of the literature, we explore the impact of axSpA on key work outcomes including ...
Nikiphorou, Elena, Ramiro, Sofia
openaire +4 more sources
S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity
BMC Rheumatology, 2020 Background S100A4 is a member of calcium binding S100 protein family well known for its role in cancer progression and metastasis. Nevertheless, S100A4 also serves as a negative regulator of bone formation. Dickkopf-1 (DKK-1), marker of bone remodelling,
Barbora Šumová +12 more
doaj +1 more source
Level of adherence to prescribed exercise in spondyloarthritis and factors affecting this adherence: a systematic review [PDF]
, 2019 Adherence is a primary determinant of the effectiveness of any intervention. Exercise is considered essential in the management of spondyloarthritis (SpA); however, the overall adherence to exercise programmes and factors affecting adherence are unknown.
Coulter, EH +4 more
core +2 more sources
99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients : a biodistribution and dosimetry study [PDF]
, 2016 Background: Biologicals directed against tumour necrosis factor (TNF) have proven their efficacy in the treatment of spondyloarthritis and rheumatoid arthritis.
Bacher, Klaus +9 more
core +2 more sources
Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
Reumatismo, 2013 In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated.
A. Spadaro +6 more
doaj +1 more source
Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]
, 2017 INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K. +2 more
core +2 more sources
Spondyloarthritis associated with inflammatory myositis: An unusual case report
Indian Journal of Rheumatology, 2019 Spondyloarthritis is an inflammatory disorder of the axial skeleton, while inflammatory myositis is an inflammatory disease affecting the striated muscles. There is no usual association of spondyloarthritis and inflammatory myositis. A 35-year-old female
Pradip Kumar Prajapati
doaj +1 more source
The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study [PDF]
, 2017 Background: In this study, we sought to compare the performance of spondyloarthritis (SpA) classification criteria sets in an international SpA cohort with patients included from five continents around the world.
Bakker, Pauline +7 more
core +2 more sources
Bone marrow edema in sacroiliitis : detection with dual-energy CT
, 2020 Objectives: To evaluate the feasibility and diagnostic accuracy of dual-energy computed tomography (DECT) for the detection of bone marrow edema (BME) in patients suspected for sacroiliitis. Methods: Patients aged 18-55 years with clinical suspicion for
Carron, Philippe +6 more
core +1 more source